---
document_datetime: 2025-12-29 14:35:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-teva.html
document_name: efavirenz-teva.html
version: success
processing_time: 0.1283774
conversion_datetime: 2025-12-31 04:05:01.725693
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Efavirenz Teva

[RSS](/en/individual-human-medicine.xml/66961)

##### Authorised

This medicine is authorised for use in the European Union

efavirenz Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Efavirenz Teva](#more-information-on-efavirenz-teva-1493)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Efavirenz Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Efavirenz Teva.

Expand section

Collapse section

## What is Efavirenz Teva?

Efavirenz Teva is a medicine that contains the active substance efavirenz. It is available as tablets (600 mg).

Efavirenz Teva is a 'generic medicine'. This means that Efavirenz Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Sustiva.

## What is Efavirenz Teva used for?

Efavirenz Teva is an antiviral medicine. It is used together with other antiviral medicines to treat adults and children aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

The medicine can only be obtained with a prescription.

## How is Efavirenz Teva used?

Treatment with Efavirenz Teva should be started by a doctor who has experience in the management of HIV infection. Efavirenz Teva must be given in combination with other antiviral medicines. It is recommended that Efavirenz Teva be taken on an empty stomach and without food, preferably at bedtime.

The recommended dose of Efavirenz Teva for adults is 600 mg once a day. Efavirenz Teva tablets are not suitable for children weighing less than 40 kg. Efavirenz-containing capsules are available for these patients.

The dose of Efavirenz Teva needs to be reduced in patients taking voriconazole (used to treat fungal infections). Patients taking rifampicin (an antibiotic) may need to take a higher dose of Efavirenz Teva.

For full details, see the summary of product characteristics (also part of the EPAR).

## How does Efavirenz Teva work?

The active substance in Efavirenz Teva, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells in the body and make more viruses. By blocking this enzyme, Efavirenz Teva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Efavirenz Teva does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Efavirenz Teva been studied?

Because Efavirenz Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Sustiva. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Efavirenz Teva?

Because Efavirenz Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Efavirenz Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Efavirenz Teva has been shown to have comparable quality and to be bioequivalent to Sustiva. Therefore, the CHMP's view was that, as for Sustiva, the benefit outweighs the identified risk. The Committee recommended that Efavirenz Teva be given marketing authorisation.

## Other information about Efavirenz Teva

The European Commission granted a marketing authorisation valid throughout the EU for Efavirenz Teva on 9 January 2012.

For more information about treatment with Efavirenz Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Efavirenz Teva : EPAR - Summary for the public

Reference Number: EMA/883956/2011

English (EN) (55.8 KB - PDF)

**First published:** 27/01/2012

**Last updated:** 27/01/2012

[View](/en/documents/overview/efavirenz-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-226)

български (BG) (93.49 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/bg/documents/overview/efavirenz-teva-epar-summary-public_bg.pdf)

español (ES) (73.42 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/es/documents/overview/efavirenz-teva-epar-summary-public_es.pdf)

čeština (CS) (147.89 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/cs/documents/overview/efavirenz-teva-epar-summary-public_cs.pdf)

dansk (DA) (115.91 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/da/documents/overview/efavirenz-teva-epar-summary-public_da.pdf)

Deutsch (DE) (117.79 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/de/documents/overview/efavirenz-teva-epar-summary-public_de.pdf)

eesti keel (ET) (115.55 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/et/documents/overview/efavirenz-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (97 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/el/documents/overview/efavirenz-teva-epar-summary-public_el.pdf)

français (FR) (58.29 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/fr/documents/overview/efavirenz-teva-epar-summary-public_fr.pdf)

italiano (IT) (133.43 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/it/documents/overview/efavirenz-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (83.14 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/lv/documents/overview/efavirenz-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (141.08 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/lt/documents/overview/efavirenz-teva-epar-summary-public_lt.pdf)

magyar (HU) (79.97 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/hu/documents/overview/efavirenz-teva-epar-summary-public_hu.pdf)

Malti (MT) (82.99 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/mt/documents/overview/efavirenz-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (119.29 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/nl/documents/overview/efavirenz-teva-epar-summary-public_nl.pdf)

polski (PL) (145.18 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/pl/documents/overview/efavirenz-teva-epar-summary-public_pl.pdf)

português (PT) (57.94 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/pt/documents/overview/efavirenz-teva-epar-summary-public_pt.pdf)

română (RO) (80.63 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/ro/documents/overview/efavirenz-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (81.45 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/sk/documents/overview/efavirenz-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (78.86 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/sl/documents/overview/efavirenz-teva-epar-summary-public_sl.pdf)

Suomi (FI) (117.18 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/fi/documents/overview/efavirenz-teva-epar-summary-public_fi.pdf)

svenska (SV) (117.97 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

27/01/2012

[View](/sv/documents/overview/efavirenz-teva-epar-summary-public_sv.pdf)

## Product information

Efavirenz Teva : EPAR - Product information

English (EN) (742.66 KB - PDF)

**First published:** 27/01/2012

**Last updated:** 03/03/2023

[View](/en/documents/product-information/efavirenz-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-950)

български (BG) (936.27 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/bg/documents/product-information/efavirenz-teva-epar-product-information_bg.pdf)

español (ES) (790.16 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/es/documents/product-information/efavirenz-teva-epar-product-information_es.pdf)

čeština (CS) (887.1 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/cs/documents/product-information/efavirenz-teva-epar-product-information_cs.pdf)

dansk (DA) (437.71 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/da/documents/product-information/efavirenz-teva-epar-product-information_da.pdf)

Deutsch (DE) (817.24 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/de/documents/product-information/efavirenz-teva-epar-product-information_de.pdf)

eesti keel (ET) (768.61 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/et/documents/product-information/efavirenz-teva-epar-product-information_et.pdf)

ελληνικά (EL) (971.43 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/el/documents/product-information/efavirenz-teva-epar-product-information_el.pdf)

français (FR) (802.46 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/fr/documents/product-information/efavirenz-teva-epar-product-information_fr.pdf)

hrvatski (HR) (835.4 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/hr/documents/product-information/efavirenz-teva-epar-product-information_hr.pdf)

íslenska (IS) (745.46 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/is/documents/product-information/efavirenz-teva-epar-product-information_is.pdf)

italiano (IT) (769.28 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/it/documents/product-information/efavirenz-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (885.53 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/lv/documents/product-information/efavirenz-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (807.85 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/lt/documents/product-information/efavirenz-teva-epar-product-information_lt.pdf)

magyar (HU) (860.92 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/hu/documents/product-information/efavirenz-teva-epar-product-information_hu.pdf)

Malti (MT) (1.01 MB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/mt/documents/product-information/efavirenz-teva-epar-product-information_mt.pdf)

Nederlands (NL) (750.51 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/nl/documents/product-information/efavirenz-teva-epar-product-information_nl.pdf)

norsk (NO) (781.12 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/no/documents/product-information/efavirenz-teva-epar-product-information_no.pdf)

polski (PL) (905.04 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/pl/documents/product-information/efavirenz-teva-epar-product-information_pl.pdf)

português (PT) (734.21 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/pt/documents/product-information/efavirenz-teva-epar-product-information_pt.pdf)

română (RO) (862.25 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/ro/documents/product-information/efavirenz-teva-epar-product-information_ro.pdf)

slovenčina (SK) (851.58 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/sk/documents/product-information/efavirenz-teva-epar-product-information_sk.pdf)

slovenščina (SL) (808.47 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/sl/documents/product-information/efavirenz-teva-epar-product-information_sl.pdf)

Suomi (FI) (765.68 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/fi/documents/product-information/efavirenz-teva-epar-product-information_fi.pdf)

svenska (SV) (723.53 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

03/03/2023

[View](/sv/documents/product-information/efavirenz-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0027/G 27/02/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Efavirenz Teva : EPAR - All Authorised presentations

English (EN) (22.83 KB - PDF)

**First published:** 27/01/2012

**Last updated:** 15/11/2013

[View](/en/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-147)

български (BG) (43.67 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/bg/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.29 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/es/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.07 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/cs/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.76 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/da/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (23.07 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/de/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.53 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/et/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.13 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/el/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (16.14 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/fr/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.86 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/hr/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (23.86 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/is/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.43 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/it/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.49 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/lv/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.7 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/lt/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.89 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/hu/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.84 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/mt/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.04 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/nl/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.67 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/no/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.7 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/pl/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.94 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/pt/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.67 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/ro/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/sk/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.94 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/sl/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.37 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/fi/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.11 KB - PDF)

**First published:**

27/01/2012

**Last updated:**

15/11/2013

[View](/sv/documents/all-authorised-presentations/efavirenz-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Efavirenz Teva Active substance efavirenz International non-proprietary name (INN) or common name efavirenz Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AG03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children 3 years of age and older.

Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts &lt; 50 cells/mm 3 , or after failure of protease inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with protease inhibitors (PIs) has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz.

## Authorisation details

EMA product number EMEA/H/C/002352

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 09/01/2012 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Efavirenz Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (189.9 KB - PDF)

**First published:** 03/10/2012

**Last updated:** 03/03/2023

[View](/en/documents/procedural-steps-after/efavirenz-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Efavirenz Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/916997/2011

English (EN) (169.52 KB - PDF)

**First published:** 27/01/2012

**Last updated:** 27/01/2012

[View](/en/documents/assessment-report/efavirenz-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Efavirenz Tenz

Adopted

Reference Number: EMA/CHMP/613927/2011

English (EN) (77.52 KB - PDF)

**First published:** 21/10/2011

**Last updated:** 21/10/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-efavirenz-tenz_en.pdf)

#### More information on Efavirenz Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/03/2023

## Share this page

[Back to top](#main-content)